Glycine/lysine acetylsalicylate inhalation - Ventaleon

Drug Profile

Glycine/lysine acetylsalicylate inhalation - Ventaleon

Alternative Names: Acti-INSP-001; Glycine/lysine acetylsalicylate inhalation - Vectura; LASAG; Lysine acetylsalicylate glycine inhalation - Vectura; Lysine acetylsalicylate/glycine inhalation - Vectura; VR 736

Latest Information Update: 29 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Activaero GmbH
  • Developer Vectura; Ventaleon
  • Class Antiplatelets; Antipyretics; Antirheumatics; Antivirals; Basic amino acids; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Salicylates; Small molecules
  • Mechanism of Action Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Influenza virus infections

Most Recent Events

  • 29 Jul 2016 Glycine/lysine acetylsalicylate inhalation is still in phase II trials in Influenza virus infections (in hospitalised patients) (Vectura pipeline, July 2016)
  • 13 Mar 2014 Activaero GmbH has been acquired by Vectura
  • 12 Feb 2013 Phase-II clinical trials in Influenza virus infections (in hospitalised patients) in Latvia, Lithuania and Spain (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top